Carambola (Averrhoa carambola L.): A Comprehensive Reference
1. Identity and Botanical Description
1.1 Scientific Name and Taxonomy
Averrhoa carambola L. is a perennial tree in the family Oxalidaceae. The family Oxalidaceae consists of over 900 species belonging to seven genera; the genus Averrhoa mainly includes three species: A. carambola, A. bilimbi L., and A. dolichocarpa Ruhayah and Sunart. The genus name honors the twelfth-century Arab physician Averroes. The word "carambola" is derived from the Sanskrit word karmaranga.
1.2 Common Names
Carambola, also known as star fruit, is the fruit of Averrhoa carambola, a species of tree native to tropical Southeast Asia. The fruit is recognized as belimbing manis or balimbing (Filipino) in many Southeast Asian regions and kamrakh in India. In Hindi it is known as Kamranga; in Gujarati as Kamrakh; in Marathi as Karambal; and in Tamil as Thambaratham or Tamarattai.
1.3 Morphology and Geographic Origin
Botanically, A. carambola is a medium-sized tree reaching up to 3–15 m tall. The edible fruit has distinctive ridges running down its sides (usually 5–6); when cut in cross-section, it resembles a star, giving it the name star fruit. The fruit is fleshy, drooping, with 5 edges (rarely 6 or 3), star-shaped in cross section, 5–8 cm long, light green or waxy yellow, sometimes dark red.
Carambola is native to the Malayan peninsula and cultivated in many parts of Southeast Asia, the Pacific Islands, and China for its fruits. It is commonly consumed in Southeast Asia, South Asia, the South Pacific, Micronesia, parts of East Asia, the United States, parts of Latin America, and the Caribbean. Averrhoa carambola has a number of different forms differing in fruit taste, texture, and shape; some are very acidic and others are sweet.
1.4 Common Forms and Preparations
The entire fruit is edible, usually raw, and may be cooked or made into relishes, preserves, garnish, and juices. It is frequently used in fruit salads and fruit platters, as a garnish in cocktail drinks and beverages, or squeezed into juice and served as a beverage. In traditional medicine, all parts of the plant have been utilized: leaves, roots, flowers, and fruits have each served as ethnomedicinal preparations in Chinese, Indian, Malaysian, and Brazilian medicine, taken as aqueous decoctions, extracts, juices, or topically applied crushed preparations. The fruit can be classified into two categories: the sour type — richly flavored, commonly prepared as juice and with more oxalic acid — and the sweet type — mild flavored, usually consumed as fresh fruit and with less oxalic acid.
2. Traditional and Historical Use
2.1 India (Ayurvedic and Folk Medicine)
In India, the juice and ripe fruits of A. carambola have been used to address scurvy, boost appetite, act as an astringent, stimulate saliva production, alleviate fever, treat hemorrhoids, relieve thirst, and act as a purgative. In both Ayurvedic and Traditional Chinese Medicine (TCM), A. carambola is valued for its diverse medical advantages, addressing conditions such as coughs, dermal fungal infections, eczema, and severe headaches.
2.2 Southeast Asia (Malaysia, Philippines, Indonesia)
In Malaysian traditional medicine, the fruit serves as a febrifuge, addresses recurrent aphthous ulcers, acts as an emetic, and aids in chest pain relief. The crushed shoots or leaves of A. carambola are commonly applied in traditional Malaysian medicine to treat headache, chickenpox, and ringworm. In addition to being eaten, the fruit is used in traditional Asian medicine to treat chickenpox, intestinal parasites, headaches, and other illnesses.
2.3 Traditional Chinese Medicine (TCM)
A. carambola is commonly known as star fruit or carambola, bearing deeply ridged, yellow-brown, edible fruit. It has been traditionally used for thousands of years in treating diabetes and diabetic nephropathy (DN), arthralgia, vomiting, lithangiuria, coughing, hangovers, and chronic paroxysmal headache.
2.4 Brazil and Latin America
The fruit is used in traditional medicines in countries such as India, China, the Philippines, and Brazil for treating various ailments, including fever, diarrhea, vomiting, and skin disease.
2.5 Broad Traditional Scope
Traditionally, A. carambola was used in ailments such as arthralgia, chronic headache, boils and pyodermas, colds, cough, epistaxis, spermatorrhea, fever, food poisoning, gastroenteritis, malaria, malarial splenomegaly, oliguria, postpartum edema, sore throat, subcalorism, and traumatic injury. The different medicinal organs of A. carambola, including leaves, roots, flowers, and the fruits, have been utilized as ethnomedicine in Chinese, Indian, Malaysian, and Brazilian medicine for a long time.
3. Key Constituents and Active Compounds
3.1 Total Phytochemical Inventory
Approximately 132 compounds have been isolated from A. carambola. Among them, flavonoids, benzoquinone, and their glycosides have been considered as biologically active substances, which are responsible for various biological activities.
3.2 Flavonoids
Investigations characterizing the secondary metabolites of A. carambola have identified two O-glycosyl flavonoid components: quercetin-3-O-β-d-glucoside and rutin. Other compounds identified include β-sitosterol, lupeol, anthraquinone glucoside, cyanidin-3-O-β-d-glucoside. Thirteen flavonoids have been isolated from the fresh sweet fruit; novel structures include 8-carboxymethyl-(+)-epicatechin methyl ester, pinobanksin 3-O-β-d-glucoside, and carambolasides M–Q. Additionally, (+)-epicatechin, aromadendrin 3-O-β-d-glucoside, helicioside A, taxifolin 3′-O-β-d-glucoside, galangin 3-O-rutinoside, and isorhamnetin 3-O-rutinoside were reported from this species for the first time.
The root and leaves of A. carambola contained bioactive flavonoids such as Lyoniresinol 3α-O-β-d-Glucopyranoside, 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione (DMDD), apigenin-6-C-β-fucopyranoside, and apigenin-6-C-(2″-O-α-rhamnopyranosyl)-β-fucopyranoside. In vivo studies confirmed anti-obese activity; fourteen compounds including four flavone glycosides and ten dihydrochalcone glycosides were isolated and identified from leaves using spectroscopic techniques.
Juice produced from carambola has a high content of total flavonoids (1345 mg CAE L⁻¹), and the composition of these compounds is dominated by flavanols, chiefly epicatechin.
3.3 Phenolic Acids and Tannins
The therapeutic potential of A. carambola is attributed to its abundance of natural antioxidants and phenolic compounds such as gallic acid in gallotannin form, catechins, and epicatechins. Phytochemical investigations have shown the presence of saponins, tannins, alkaloids, and flavonoids.
3.4 Benzoquinone: DMDD
The benzoquinone DMDD (2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione) has been considered among the biologically active components with extensive biological properties, including anti-hyperglycemic, anti-hyperlipidemic, anti-obesity, anti-inflammatory, hepatoprotective, anti-tumor, cardioprotective, and neuroprotective activities.
3.5 Terpenes and Norisoprenoids
Carotenoid-derived components, mainly C₁₃- and C₁₅-norisoprenoids, contribute greatly to the flavor of star fruit. Major terpenes identified by NMR and MS methods include cis-abscisic acid, trans-abscisic acid, trans-abscisic alcohol, (6S,9R)-vomifoliol, cis-abscisic acid β-D-glucopyranosyl ester, trans-abscisic alcohol β-D-glucopyranoside, (6S,9R)-roseoside, and cis-abscisic alcohol β-D-glucopyranoside.
3.6 Other Secondary Metabolites
Key constituents also include alkyl phenols, benzoquinones, carotenoids, β-sitosterol, lupeol, anthraquinone glucoside, and p-anisaldehyde. Phytochemical screening has validated the occurrence of alkaloids, flavonoids, phenolic compounds, terpenoids, steroids, and carbohydrates.
3.7 Oxalic Acid and Caramboxin
The fruit contains oxalic acid and caramboxin. Caramboxin (CBX) is a non-proteinogenic amino acid similar to phenylalanine, but containing hydroxyl, methoxy, and carboxyl substituents on the aromatic ring. Like phenylalanine, it contains a single chiral atom, meaning two enantiomers are possible, with the (S) form being the one found in the plant.
3.8 Minerals and Vitamins
Star fruit is a rich source of minerals and vitamins including magnesium, potassium, and vitamin C. It also serves as a rich source of essential nutrients including copper, potassium, folate, and pantothenic acid. The potassium content in ripe star fruit is approximately 125 mg/100 g.
4. Established Mechanisms of Action
4.1 Antioxidant Mechanisms
The antioxidant effects are mediated via L-ascorbic acid, epicatechin, and gallic acid. Leaves are rich in phenolic and flavonoid components, closely associated with antioxidant effects; in a systematic comparison between twenty locally available fruits planted in Sri Lanka, A. carambola had the third most potent antioxidant properties based on FRAP and DPPH activities, total flavonoid content, total phenolic content, and vitamin C content.
4.2 Hypoglycemic Mechanisms
Insoluble fiber-rich fractions from carambola pomace can effectively adsorb glucose, retard glucose diffusion, postpone the release of glucose from starch, and inhibit the activity of α-amylase to different extents. An in vitro study on cultured pancreatic beta-cells found the compound DMDD extracted from star fruit to attenuate inflammation and cell apoptosis; the same compound increased glucose-stimulated insulin secretion. In summary, A. carambola can attenuate oxidative injury and inflammatory response in rat models by enhancing antioxidant enzyme activities and decreasing inflammatory cytokine levels, which result in insulin secretion as well as blood glucose and blood lipid metabolism regulation.
4.3 Anti-Hyperlipidemic Mechanisms
The ethyl acetate fraction of the methanolic extract of A. carambola leaves showed anti-hyperlipidemic effects by downregulating SREBP-2, upregulating ABCA1 and LDL-R, and ameliorating lipoprotein lipase and HMG-CoA reductase in hyperlipidemic rats.
4.4 Antihypertensive Mechanisms
Hypotensive effects are mediated via apigenin, which blocks extracellular Ca²⁺ influx, the effects being associated with the presence of apigenin as a secondary metabolite of A. carambola leaves. Animal studies have demonstrated blood pressure-lowering effects in normotensive rats following administration of aqueous leaf extract.
4.5 Neurotoxic Mechanisms (Caramboxin)
A shift to an excitatory state of the central nervous system (CNS) by caramboxin occurs through activation of excitatory neuroreceptors and inhibition of GABA receptors, leading to mental confusion, seizures, and status epilepticus seen with star fruit intoxication. The neurotoxic effect of caramboxin appears to inhibit the GABAergic system, which is the major inhibitory system in the central nervous system (CNS), involving changes ranging from hiccups and confusion to more serious conditions such as seizures and death.
4.6 Nephrotoxic Mechanisms (Oxalic Acid)
In some individuals, ingestion of star fruit may lead to nephrotoxicity and neurotoxicity. The nephrotoxic effect is due to oxalate deposition in renal tubules, resulting in acute tubular necrosis and interstitial nephritis.
5. Scientific Evidence by Health Area
Important note on evidence quality: Even though A. carambola is a very promising candidate in the development of functional food and the pharmaceutical industry, reports on its bioactivities have only been conducted in vivo and in vitro and there is a gap in research regarding clinical settings and safety. The sections below explicitly distinguish preclinical from clinical evidence.
5.1 Antioxidant Activity
In vitro / preclinical evidence (moderate volume, consistent): Pinobanksin 3-O-β-d-glucoside and carambolasides M–Q showed potent ABTS radical cation scavenging activity (IC₅₀ = 2.3–5.3 μM), more potent than L-ascorbic acid (10.5 μM). Rich phenolic and flavonoid content of methanol extract of A. carambola leaves demonstrated moderate dose-dependent free radical scavenging activity (IC₅₀: 62.0 μg/mL for DPPH and 6.0 μg/mL for ABTS). Dihydrochalcone C-glycosides isolated from the fruit exhibited ABTS radical cation scavenging activity with IC₅₀ values ranging from 3.9 to 7.6 μM, more potent than L-ascorbic acid (IC₅₀ = 11.6 μM).
Clinical evidence: No controlled human clinical trials on antioxidant effects of carambola supplementation were identified in the literature reviewed.
5.2 Antidiabetic / Hypoglycemic Activity
In vitro evidence: Insoluble fiber-rich fractions from carambola pomace (including insoluble dietary fiber, alcohol-insoluble solid, and water-insoluble solid) effectively adsorbed glucose, retarded glucose diffusion, postponed the release of glucose from starch, and inhibited the activity of α-amylase.
Animal (in vivo) evidence: Extracts from the roots of Averrhoa carambola L. clearly decreased the level of fasting blood glucose in diabetic (STZ-induced) mice after 21 days of treatment. The serum concentrations of free fatty acids, total cholesterol, and triglycerides in metformin- and EACR-treated groups (at 600 and 1200 mg/kg/day) were lower than those concentrations in STZ-diabetic mice. Carambolaflavones A and B were reported for their hypoglycemic effect in rats.
Clinical evidence: So far, the evidence lies in experimental animal studies and one in vitro study, and thus clinical studies are needed to assess clinically relevant antidiabetic effects in humans. No adequately powered, controlled human trials were identified.
5.3 Anti-Hyperlipidemic Activity
In vitro / animal evidence: The methanolic extract of A. carambola leaves (MEACL) and its fractions were evaluated for anti-hyperlipidemic and antioxidant activities using FRAP, ABTS, and DPPH radical-scavenging assays, and for inhibitory activity toward pancreatic lipase and HMG-CoA reductase in vitro. The ethyl acetate fraction showed more effective anti-hyperlipidemic and antioxidant effects than other fractions and downregulated SREBP-2 while upregulating ABCA1 and LDL-R; it significantly ameliorated dyslipidemia in a rat model of poloxamer-407-induced acute hyperlipidemia by modulating LPL, PL, HMG-CoA reductase, and cholesterolgenesis-related factors.
Clinical evidence: Preclinical only. No human trials on lipid outcomes were identified in the reviewed literature.
5.4 Anti-Inflammatory Activity
Animal evidence: The topical anti-inflammatory effects of crude ethanolic extract of A. carambola leaves, its hexane, ethyl acetate, and butanol fractions, and two isolated flavonoids were evaluated on skin inflammation using a croton oil-induced ear edema model of inflammation in mice. Plant extracts showed strong antioxidant activity, with comparable results to standard antioxidants, and anti-inflammatory assays indicated a significant decrease in inflammatory markers; research confirmed the potential antioxidant and anti-inflammatory activities of Averrhoa carambola leaves, supporting their traditional medicinal uses.
Clinical evidence: Preclinical only.
5.5 Antihypertensive Activity
Animal evidence: Soncini et al. studied the effects of the Averrhoa carambola aqueous extract (AEAc) of leaves in anesthetized normotensive rats; both in vivo and in vitro, there was a lowering of arterial blood pressure. The mechanism proposed involves calcium channel blockade mediated by apigenin.
Clinical evidence: Preclinical only.
5.6 Hepatoprotective Activity
Animal evidence: The fruit juice of A. carambola exhibited potential liver-protective effects. Hepatoprotective properties have been demonstrated in mice with STZ-induced diabetes, where the extract reduced MDA and cAMP levels and increased SDH, MDA, and SOD activities in the liver.
Clinical evidence: Preclinical only.
5.7 Antimicrobial and Antifungal Activity
Pharmacological investigations on A. carambola have established anti-inflammatory, antimicrobial, antifungal, antitumor, and anti-ulcer activities. The stem bark has shown antimicrobial and antifungal activity. These findings are from in vitro studies; no clinical trials have been conducted.
5.8 Antitumor / Anticancer Activity
In vitro and animal evidence: Various studies have shown that an alcoholic extract from the stems of A. carambola was used against brain tumor cells, while an extract from the leaves was more effective against liver cancer cells. Selective activity against brain tumor cells was observed with an alcoholic extract from the stems of A. carambola, while an extract from the leaves was effective against liver carcinoma cells.
Clinical evidence: No human clinical trials on anticancer activity of carambola have been identified. All evidence remains in vitro and in animal models.
5.9 Anti-Obesity Activity
Animal evidence: Averrhoa carambola L. is reported for its anti-obese and anti-diabetic activities. A study investigated its aqueous methanol leaf extract (CLL) in vivo anti-obese activity along with the isolation and identification of bioactive compounds and their in vitro α-glucosidase inhibition. CLL improved all obesity complications and exhibited significant activity in an obese rat model.
Clinical evidence: Preclinical only.
5.10 Neuroprotective Activity
Animal evidence: Roots of A. carambola have shown potent neuroprotective effects against memory deficits and neuron apoptosis in APP/PS1 transgenic Alzheimer's disease mice. DMDD improved spatial learning, reduced neuronal loss, and inhibited Aβ1-42-induced neurodegeneration.
Clinical evidence: Preclinical only.
6. Body Systems and Health Areas Associated with Carambola
Pharmacological studies have revealed that crude extracts or monomeric compounds from A. carambola exhibit multiple bioactivities, such as anti-oxidant, anti-hyperglycemic, anti-obesity, anti-hyperlipidemic, anti-tumor, anti-inflammatory, hepatoprotective, cardioprotective, anti-hypertensive, neuroprotective, and others. The body systems most associated with carambola research include:
- Metabolic/Endocrine system: Blood glucose regulation, lipid metabolism, insulin secretion, and obesity management — primarily studied via DMDD and fiber constituents.
- Renal system: Both as a subject of nephrotoxicity (oxalate/caramboxin) and, historically, as a diuretic and treatment for urinary stones (lithangiuria) in traditional medicine.
- Cardiovascular system: Antihypertensive effects (apigenin/calcium channel), anti-hyperlipidemic effects (HMG-CoA reductase inhibition), cardioprotective potential.
- Hepatic system: Hepatoprotective activity demonstrated in animal models.
- Central nervous system: Neuroprotective effects of DMDD in Alzheimer's models; conversely, neurotoxicity due to caramboxin.
- Immune/Inflammatory system: Anti-inflammatory properties demonstrated in topical and systemic animal models.
- Integumentary system: Traditional topical uses for skin disorders, ringworm, chickenpox; anti-inflammatory skin data from mouse models.
- Digestive system: Traditional use for diarrhea, vomiting, gastroenteritis, anti-ulcer activity noted in pharmacological reviews.
7. Dosage Forms and Reported Dosages
The following dosages are reported only as used or described in cited scientific publications. No therapeutic dosage has been established in human clinical trials.
- Root extract (EACR) in STZ-diabetic mice: 600 and 1200 mg/kg/day for 21 days were the doses employed in the hypoglycemic animal study by the Karger-published Cellular Physiology and Biochemistry research group.
- Fruit juice (EACJ) in STZ-diabetic mice: Mice were injected with STZ (120 mg/kg body weight); juice was administered by gavage at 25, 50, and 100 g/kg body weight per day and compared with metformin (320 mg/kg body weight/day) for 21 days.
- Leaf extract (MEACL) — anti-inflammatory study in vitro: Methanol extract of A. carambola leaves (MEACL) at 50–375 μg/ml demonstrated dose-dependent activity.
- Leaf extract in analgesic test: On acetic acid-induced analgesic test, plant extract exhibited a significant writhing reflex inhibition by 11.12% and 40.28% (p <0.01) at doses of 250 mg/kg.
- Dosage form in traditional medicine: Traditionally administered as fresh fruit, fresh juice, aqueous decoctions of leaves, or topically applied crushed leaves — no standardized preparation exists in any reviewed pharmacopeia or official monograph.
8. Safety Considerations and Drug Interactions
8.1 Nephrotoxicity
Although star fruit-induced oxalate nephrotoxicity in those with existing renal impairment is well documented, reports on its effect on those with normal renal function are infrequent. Two unique clinical presentation patterns of nephrotoxicity were reported following consumption of the fruit as a remedy for diabetes mellitus — the first in a patient with normal renal function developing acute kidney injury, and the second believed to be the first reported case of chronic kidney disease (CKD) due to prolonged and excessive consumption of star fruits.
Large amounts of star fruit ingestion, or even smaller amounts on an empty stomach, may provoke simultaneous acute renal failure and neurotoxicity in people with previously normal renal function. The sour carambola contains more oxalate than the sweet fruit.
8.2 Neurotoxicity and the Role of Caramboxin
In individuals who present with simultaneous neurotoxic and nephrotoxic effects, a proposed sequence of events is: ingestion of large amounts of oxalate in star fruit causes acute oxalate nephropathy and acute renal failure, followed by neurotoxic effects (mostly hiccups) triggered by caramboxin that accumulates due to renal failure, and finishes as soon as renal function improves. It is well known that this fruit is toxic in chronic kidney disease; if ingested, patients with renal failure can have seizures, hiccups, mental confusion, coma, and even death. Formerly, it was believed that patients with normal renal function could ingest the fruit without any problems. However, isolated cases in literature proved that massive ingestion of this fruit can lead to acute kidney injury and neurotoxic effects.
The consumption of substantial amounts of star fruit or its juice on an empty stomach is not recommended, regardless of whether individuals have normal kidney function or not.
8.3 Treatment of Toxicity
When toxicity occurs, intense hemodialysis is used to lower the concentration of caramboxin and oxalic acid, as these are water soluble.
8.4 Risk Factors for Toxicity
The presence of chronic kidney disease, gastroenteropathies, chronic pancreatitis, dehydration, consumption on an empty stomach, and higher concentration of oxalate in the fruit represent risk factors for toxicity.
8.5 CYP3A4 / Drug Metabolism Interactions
Like grapefruit, carambola is considered to be a potent inhibitor of seven cytochrome P450 isoforms. These enzymes are significant in the first-pass elimination of many medications, and thus the consumption of carambola or its juice in combination with certain prescription medications can significantly alter drug levels. The inhibitory effects of star fruit (Averrhoa carambola) on human CYP3A activity have been reported. This interaction has potential relevance for any medication that is a CYP3A4 substrate, including immunosuppressants, calcium channel blockers, and certain statins.
8.6 Negative Inotropic and Chronotropic Effects
The plant possesses hypocholesterolemic, hypoglycemic, hypotensive, nephrotoxic, neurotoxic, negative inotropic, and chronotropic effects. These cardiac effects, demonstrated in isolated tissue and animal preparations, have implications for patients with cardiac arrhythmias or those taking cardiac medications.
8.7 Antinutrients
Phytate and tannin content in half-ripe and ripe carambola are present at 0.06–0.04 mg/100g and 0.25–0.16 mg/100g, respectively; as ripening increases, phytate and tannin content decrease. Phytic acid has the capability to chelate divalent elements like calcium, thus decreasing their bioavailability.
9. Summary of Evidence Strength
The overall body of scientific evidence for Averrhoa carambola as a therapeutic agent remains predominantly preclinical. Reports on its bioactivities have only been conducted in vivo and in vitro, and there is a gap in research regarding clinical settings and safety. The most mechanistically developed areas are antidiabetic activity (particularly via DMDD and fiber constituents), antioxidant activity, and anti-hyperlipidemic effects — all substantiated in cell culture and rodent models. The toxicological profile (nephrotoxicity, neurotoxicity via caramboxin, and CYP3A4 inhibition) is supported by multiple published clinical case reports and in vitro mechanistic studies. No adequately powered, randomized controlled trials in humans are available for any of the purported health benefits of carambola as of the most recent peer-reviewed reviews.
References
Go back